Biomarin Pharmaceutical (BMRN) Buildings (2010 - 2013)

Biomarin Pharmaceutical has disclosed Buildings across 4 years of filings, most recently posting $159.1 million for Q4 2013.

• Quarterly Buildings rose 9.97% year-over-year to $159.1 million in Q4 2013, while the trailing twelve-month figure through Dec 2013 was $159.1 million (up 9.97% YoY) and the FY2013 annual result came in at $159.1 million, up 9.97% from the prior year.
• Buildings climbed to $159.1 million in Q4 2013, from $154.5 million in the prior quarter.
• Over five years, Buildings peaked at $159.1 million in Q4 2013 and troughed at $138.0 million in Q4 2010.
• A 4-year average of $146.1 million and a median of $144.2 million in 2012 frame the typical range for Buildings.
• Annual changes were most pronounced in 2012 — Buildings grew 2.27% — and 2013, when it rose 9.97%.
• Tracing BMRN's Buildings over 4 years: stood at $138.0 million in 2010, then gained by 2.51% to $141.5 million in 2011, then climbed by 2.27% to $144.7 million in 2012, then increased by 9.97% to $159.1 million in 2013.
• Business Quant data shows BMRN's Buildings at $159.1 million in Q4 2013, $154.5 million in Q3 2013, and $147.0 million in Q2 2013.